Home/Orthogon Therapeutics/Mark R. Spyvee, D. Phil.

MR

Mark R. Spyvee, D. Phil.

Vice President, Medicinal Chemistry

Orthogon Therapeutics

Therapeutic Areas

Infectious Disease Oncology

Orthogon Therapeutics Pipeline

Drug	Indication	Phase
Anti-polyomavirus program	BK virus infection (e.g., nephropathy in transplant patients)	Preclinical

Leadership Team at Orthogon Therapeutics

Ali H. Munawar, Ph.D.

Chief Executive Officer & Founder

Stephen Weeks, Ph.D.

Director, Structural Biology & Biophysics

View full Orthogon Therapeutics profile